ClinEdge, LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$23,987	7
2022	Research	$869,348	32
2021	Research	$1,313,366	59

Breakdown

Who paid Research payments · program years 2021–2023

Partner Therapeutics, Inc. $2,008,519 36 payments
Jazz Pharmaceuticals Inc. $166,385 39 payments
Purdue Pharma L.P. $24,560 17 payments
Genentech, Inc. $7,197 5 payments
Adlon Therapeutics L.P. $40 1 payment

Studies the money was for Research payments · program years 2021–2023

Scope $2,008,519 36 payments
A Phase 4 Multicenter, Open-Label, Single-Arm Study of Safety, Tolerability, Effectiveness and Treatment Optimization in Participants Switching From Xyrem to Xywav for the Treatment of Narcolepsy $103,670 28 payments
Solriamfetols Effect on Cognitive Health in Apnea Participants During A Randomized Placebo Controlled Study: A 5 Week Double Blind, Placebo Controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function $62,715 11 payments
An open-label, multicenter, multiple-dose, safety and tolerability study of Adhansia XR extended-release capsules in children 4 to 12 years of age $24,600 18 payments
Transmission Study Household $7,197 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.